A closely watched next-generation blood thinner being developed by Bristol Myers Squibb and Johnson & Johnson failed in one of three late-stage trials.
The drug, milvexian, is a selective factor XIa inhibitor designed to prevent harmful clotting in the blood. It’s being tested in three Phase 3 trials, in cases of acute coronary syndrome, and to address atrial fibrillation and prevent secondary strokes. BMS reported Friday that it’s shutting down the first trial, for acute coronary syndrome.
Acute coronary syndrome is an umbrella term for situations in which blood flow to the heart muscle suddenly drops due to factors like a clot or heart attack. BMS reported that an interim analysis showed milvexian is unlikely to meet the primary endpoint of the trial.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
